Drug Device Combination Products Market Analysis & Forecast: 2026-2033

Drug Device Combination Products Market Size and Share Analysis: (2026 - 2033)

The Drug Device Combination Products Market is anticipated to grow at a CAGR of 7.6% with USD 187.1 Bn in 2026 and is expected to reach USD 312.5 Bn in 2033. Rising incidence of chronic ailments, increasing demand for personalized drug delivery systems, increasing acceptance of self-medication equipment, and technological progress in injection and inhalation therapy are among the key factors driving the market’s growth.

Key Takeaways from the Drug Device Combination Products Market Report

• Based on product, drug eluting stents will have a dominating market share of 30% in the year 2026, owing to the wide application of these devices in minimally invasive cardiovascular surgeries. As per statistics from the World Health Organization, cardiovascular diseases claim 17.9 million lives each year, accounting for 32% of all deaths worldwide.
• In terms of application, the cardiovascular segment is projected to dominate the market by holding 36% share in 2026. This is due to high global prevalence of heart diseases. As per the Centers for Disease Control and Prevention, heart disease is the leading cause of death across the globe, indicating continued growth of drug-device combination products in the cardiovascular category.
• By end user, the hospitals segment is estimated to command the maximum market share of 62% by 2026 due to the presence of a large number of patients, advanced infrastructure, and increased number of surgeries and interventions. According to the American Hospital Association, more than 33 million patients are treated in hospitals in the US alone every year, indicating the significance of hospitals in administering such complex therapies.
• The North American region will account for the largest market share of about 42% in terms of drug-device combination products globally by 2026 due to its existing healthcare infrastructure and research and development initiatives. According to the Centers for Medicare & Medicaid Services, the total healthcare expenditure in the US was expected to be around USD 5.3 trillion in 2024, accounting for 18% of the country’s GDP.

Segmental Insights

To learn more about this report, Request Free Sample

Why is Drug Eluting Stents Segment Acquiring the Largest Market Share?

Drug eluting stents are anticipated to account for the largest share of the drug-device combination products market in 2026, representing approximately 30% of the total market. This dominance is driven by their extensive use in minimally invasive cardiovascular procedures, particularly for the treatment of coronary artery disease.

The development of stent technology has improved treatment outcomes through advancements in drug-coated surfaces and biocompatibility. There is a growing trend toward less invasive methods, along with an increase in availability of interventional cardiology services.

In March 2026, Abbott Laboratories launched the XIENCE Skypoint drug-eluting stent in India, an advanced coronary stent designed for complex artery blockages with improved flexibility, deliverability, and clinical outcomes.

Why is Cardiovascular Segment Dominating the Market?

To learn more about this report, Request Free Sample

The cardiovascular segment is forecasted to remain dominant in the market by holding a market share of nearly 36% by 2026, owing to the substantial global disease burden of heart diseases, along with the rising number of interventions. The exacting nature of cardiovascular diseases necessitates the development of effective treatment approaches in the form of drug-device combinations like stents.

Moreover, the rising acceptance of catheterization and less-invasive procedures is leading to better results and shorter stays in hospitals, thereby driving segment growth. Increased investment in healthcare and better availability of cardiac care treatments globally are contributing to the dominance of this segment.

In April 2026, Medtronic announced FDA approval and U.S. launch of its Mosaic Neo mitral bioprosthetic heart valve, a next-generation cardiovascular implant designed for minimally invasive and robotic-assisted cardiac surgery.

Which End User Segment Dominates the Market?

Hospitals account for the largest share of around 62% in 2026 due to their advanced infrastructure, access to skilled healthcare professionals, and ability to manage high patient volumes. Hospitals are equipped with specialized facilities required for complex procedures involving drug-device combination products, including cardiovascular interventions, cancer therapies, and diabetes management.

Growing cases of chronic illnesses are adding to the hospital demand. According to the WHO, non-communicable diseases cause 74% of all deaths worldwide, and the management of such diseases requires regular treatment and monitoring, which is done mainly in hospitals. These two factors are reinforcing hospitals as the dominant end-user segment.

Market Drivers

Rising Adoption of Advanced Drug Delivery Technologies is transforming the Drug-Device Combination Products Market

Developments in drug delivery technologies are playing a key role in the expansion of the drug-device combination products market. Advances such as pre-filled syringes, auto-injectors, inhalers, and smart infusion pumps have made treatment more accurate and effective while ensuring patient compliance and convenience, particularly in the case of chronic disorders. Combination products are helping deliver medicines in a targeted manner, lowering the risk of medication errors.

According to the U.S. Food and Drug Administration, combination products are one of the fastest-growing segments, with the FDA reviewing hundreds of combination product applications annually, reflecting strong innovation and regulatory activity in this field.

Rising Burden of Chronic Diseases is driving demand for Drug-Device Combination Products

The rise in incidence of chronic diseases such as heart problems, diabetes, cancer, and breathing issues is one of the most important factors that have propelled the development of drug-device combination products. This is because such diseases need long-term treatment using advanced methods of delivering drugs with utmost precision to patients, and in many cases, at home. Products like insulin pumps, drug-eluting stents, and inhalers deliver drug therapy precisely without causing side effects, and thus their use continues to grow in various countries.

According to the World Health Organization, chronic diseases (noncommunicable diseases) account for 74% of all global deaths, equivalent to 41 million people annually, underscoring the massive demand for effective and integrated treatment solutions.

Current Events and Their Impact on the Drug Device Combination Products Market

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Drug Device Combination Products Market Trends

• Rising adoption of minimally invasive delivery systems (drug-eluting stents, inhalers, infusion pumps) is driving faster recovery and better outcomes.
• Growing chronic disease burden is boosting demand for long-term drug-device therapies. Diabetes cases are expected to reach 643 million by 2030, increasing use of insulin pumps and injectables.
• Strong growth in biologics and self-injection devices (auto-injectors, prefilled syringes) supported by rapid FDA approvals in combination products.
• Rise of smart and connected drug delivery systems improves adherence, as WHO notes 50% of patients with chronic diseases do not take medications as prescribed.
• Growth in the number of people suffering from heart diseases promotes development in drug-eluting stents and interventional devices.

Regional Insights

To learn more about this report, Request Free Sample

North America Dominates Owing to High Burden of Chronic Diseases and Strong Regulatory Support

North America will lead the drug-device combination product market in terms of revenue generation, with a market share of 42%, by the end of 2026, due to advancements in healthcare facilities and heavy investments in research and development.

The high prevalence of chronic diseases in the region is one of its strengths, as cardiovascular diseases continue to be the number one killer in the U.S., accounting for 1 out of every 5 deaths (CDC). The FDA regulations also contribute to the fast approval of the combination therapy products.

In March 2024, Boston Scientific received U.S. FDA approval for its AGENT Drug-Coated Balloon, the first coronary drug-coated balloon in the United States for treating in-stent restenosis.

Asia Pacific Drug Device Combination Products Market Trends

The Asia-Pacific region is likely to dominate the drug-device combination products market between 2026 and 2033 owing to an increase in the incidence of chronic diseases, improvement in healthcare infrastructure, and adoption of innovative medical devices in the region.

The International Diabetes Federation estimates that the region makes up the greatest proportion of global diabetes patients (60% of the global diabetic population). This implies an increased demand for insulin pumps, inhalation devices, and implants.

Growing Chronic Disease Burden is Accelerating the Drug Device Combination Products Market Demand in United States

The U.S. market for drug-device combination products is experiencing significant growth, spurred on by the prevalence of chronic illnesses, well-developed health care facilities, and the swift acceptance of novel drug delivery methods.

Another feature of the U.S. market is prompt regulation approval and high levels of research and development by major companies in this field. The U.S. Food and Drug Administration continue its policy of promoting innovations in combination drugs through faster approvals of such innovative drugs.

Japan Drug Device Combination Products Market Trends

The Japan drug device combination products market is growing steadily, driven by a rapidly aging society and a high level of patients suffering from chronic illnesses. Japan has one of the world’s oldest societies, with close to 30% of its population being more than 65 years old. As a result, there is an increased need for cardiovascular implants, insulin delivery devices, and ophthalmology drug-device combinations.

As per WHO, the prevalence of non-communicable diseases has been increasing in Japan, where the mortality rate is mainly due to such conditions, thus emphasizing the requirement for more advanced therapeutic and interventional devices.

In April 2026, the Pharmaceuticals and Medical Devices Agency (PMDA) updated multiple regulatory and review documents, including electronic review reports for new drugs and device-related evaluations.

Who are the Major Companies in Drug Device Combination Products Industry

Some of the major key players in Drug Device Combination Products are AbbVie Inc. (Allergan), Terumo Corporation, GlaxoSmithKline PLC, Novartis AG, Medtronic PLC, Abbott Laboratories, Boston Scientific Corp., W L Gore and Associates Inc., Stryker Corporation, and Becton, Dickinson and Company.

Key News

• In April 2026, Medtronic announced FDA approval and U.S. launch of its Mosaic Neo™ mitral bioprosthetic valve, designed for minimally invasive and robotic-assisted heart valve replacement procedures.
• In March 2026, Boston Scientific received FDA clearance for the Asurys Fluid Management System, used in minimally invasive urology and endoscopic procedures.

Market Report Scope

Analyst Opinion

• The market is characterized by high unmet medical needs instead of optional demands. As per statistics published by the World Health Organization, 74% of deaths in the world occur because of NCDs, thus making it essential to have an endless demand for combination products.
• Cardiovascular health continues to be an important growth driver, given the millions of minimally invasive treatments (e.g., stent placement and catheterization procedures) conducted each year, where drug-eluting and coated medical devices are commonly used.
• Diabetes management is a key structural driver, with the International Diabetes Federation reporting 537 million adults living with diabetes worldwide, pushing demand for insulin pumps, auto-injectors, and connected drug delivery systems.
• The integration of technology has changed the marketplace landscape, where an increasing number of intelligent devices are used in the process of drug delivery (such as wearable injectors, smart inhalers, and pump devices). The U.S. Food and Drug Administration are actively promoting quick approvals of those solutions.
• Long-term outlook remains strongly positive, driven by aging global populations and rising chronic disease prevalence, ensuring sustained demand for advanced drug-device combination products across both developed and emerging healthcare markets.

Market Segmentation

• By Products (Revenue, USD Bn, 2021-2033)
  • Drug Eluting Stents
  • Transdermal Patches
  • Infusion Pumps
  • Drug Eluting Balloon
  • Inhalers
  • Other Products
• By Application (Revenue, USD Bn, 2021-2033)
  • Cardiovascular
  • Diabetes
  • Cancer Treatment
  • Respiratory Diseases
  • Other Applications
• By End User (Revenue, USD Bn, 2021-2033)
  • Hospitals
  • Ambulatory Surgical Centers
  • Other End User
•  By Region (Revenue, USD Bn, 2021-2033)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • Central Africa
    • North Africa
• Key Players
  • AbbVie Inc. (Allergan)
  • Terumo Corporation
  • GlaxoSmithKline PLC
  • Novartis AG
  • Medtronic PLC
  • Abbott Laboratories
  • Boston Scientific Corp.
  • W.L. Gore & Associates Inc.
  • Stryker Corporation Becton
  • Becton, Dickinson and Company

Sources

Primary Research Interviews

• Cardiologists
• Endocrinologists
• Pulmonologists
• Hospital administrators
• Ambulatory surgical center (ASC) managers
• Medical device distributors
• Key opinion leaders (KOLs) in cardiology, diabetes, and interventional medicine

Databases

• World Health Organization
• Centers for Disease Control and Prevention
• National Institutes of Health
• Organisation for Economic Co-operation and Development

Magazines

• MedTech Dive
• Pharmaceutical Executive
• Medical Device & Diagnostic Industry (MD+DI)
• Fierce Biotech

Journals

• Journal of Controlled Release
• Biomaterials
• The Lancet (Cardiology / Diabetes sections)
• Drug Delivery and Translational Research
• Journal of Medical Devices

Newspapers

• The Wall Street Journal
• The New York Times
• Financial Times
• Reuters Health News

Associations

• U.S. Food and Drug Administration (Office of Combination Products)
• American Heart Association
• American Diabetes Association
• Advanced Medical Technology Association (AdvaMed)
• European Society of Cardiology

Public Domain Sources

• Company annual reports and investor presentations
• Government healthcare ministry publications (U.S., EU, Japan, India)
• Clinical trial registries such as ClinicalTrials.gov
• World Health Organization global disease burden reports
• FDA combination product regulatory guidance documents

Proprietary Elements

• CMI Data Analytics Tool
• CMI proprietary repository (10+ years historical healthcare and medical device intelligence database)